You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. New Broad-Acting Cell Wall Antibiotics for Biodefense

    SBC: MAXTHERA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A bioterrorist arsenal is likely to include a broad spectrum of bacterial species including the Category A pathogens Yersinia pestis (plague), a Gram-negative species, and Bacillus anthracis (anthrax), a Gram- positive species. Broad-spectrum antibiotics are potentially the most valuable for biodefense because these agents can be used quickly even in the absenc ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical study of GMCI in Pancreatic Cancer

    SBC: ADVANTAGENE, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 diagnoses and deaths per year. Multimodality therapy, including surgery, radiation and chemotherapy, have not made a significant impact on the outcome and serve mostly as palliation. Thus, new treatment ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Identification of Ebola Virus Entry Inhibitors

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Ebola virus (EBOV) causes periodic outbreaks of severe viral hemorrhagic fevers in Africa with high mortality rates in infected patients. EBOV can be used in acts of bio-terrorism because of its highly infectious nature and stability in aerosolized form. It is classified as a Category A bioweapons agent by the Centers for Disease Control and Prevention (CDC). C ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Type III Secretion Inhibitors for Anti-Infective Therapy

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is a common and extremely virulent cause of serious infections in immune- compromised/suppressed patients (e.g., HIV and cancer), cystic fibrosis patients, and those on mechanical ventilation or with burn wounds. Frequent antibiotic resistance and the highly virulent nature of P. aeruginosa make it deadlier than most other bacteria. New c ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. New Broad-Spectrum Antibiotics Targeting CoA Synthesis

    SBC: MAXTHERA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We intend to develop antibacterials that are different from previous chemical classes and that act on entirely new targets. In prior work we identified a series of tetrahydro-a-carbolines that are potent inhibitors of a novel, broad-spectrum antibacterial target from E. coli, phosphopantetheine adenyl transferease (PPAT). PPAT catalyzes a rate-limiting step in ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. siRNA Intervention Strategies for Influenza Infection

    SBC: ALNYLAM PHARMACEUTICALS            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this proposal is the discovery and development of novel drugs to be used in a disease intervention strategy for influenza (flu) infection that comprise short interfering RNAs (siRNAs), the molecules that induce RNA interference. To achieve this goal we will design, synthesize and test a pool of chemically optimized siRNAs targeting highly conserved ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. A Mucosal Vaccine for HSV-2

    SBC: Biomedical Research Models, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 1 out of every 5 Americans is infected with herpes simplex virus type 2 (HSV-2). Localized genital infection by HSV-2 results in painful recurring genital lesions while disseminated infection can involve multiple visceral organs and lethal encephalitis. We have developed a new heterologous immunization protocol composed of a DNA vaccine follow ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. DEVELOPMENT OF INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS DNA REPLICATION

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): New antibiotics based on novel chemical scaffolds against new bacterial targets are vital to reducing the tide of tuberculosis (TB) infection worldwide. Due to the lengthy treatment requirements and the difficulty in achieving treatment compliance, there is an increasing rate of development of multi-drug resistant TB. In addition, the coinfection of TB with HIV ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government